Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK2982772 TID in Healthy Japanese Males
NCT03590613Phase 1Completed
- Sponsor
- GSK
- Start
- Jul 2018
- Primary completion
- Sep 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK2982772 in autoimmune diseases (4 arms), sponsored by GSK. Primary endpoints: Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs), Change From Baseline in Clinical Chemistry Parameters and 5 more. Started Jul 2018; status: completed.
02
Drugs
GSK2982772
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT03590613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03590613.